Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions

AbstractTo evaluate the local control (LC), progression free survival (PFS), out-field PFS, overall survival (OS), toxicity and failure predictors of SRT in a series of various sites oligometastatic CRC patients. Patients with oligometastatic CRC disease were analyzed retrospectively. The SRT prescribed dose was dependent on the lesion volume and its location. 102 consecutive oligometastatic CRC patients (150 lesions) were included. They underwent SRT between 2012 and 2015. Median prescription dose was 45  Gy (median dose/fraction was 15 Gy/3 fractions biological equivalent dose (BED10) 112.5  Gy). Median follow-up was 11.4 months. No patients experienced G3 and G4 toxicity. No progression was found in 82% (radiological response at 3 months) and 85% (best radiological response) out of 150 evaluable lesions. At 1 and 2 years: LC was 70% and 55%; OS was 90% and 90%; PFS was 37% and 27% ; out-field PFS was 37% and 23% respectively. Progressive disease was correlated with BED10 (better LC when BED10 was  ≥ 75 Gy (p <  0.0001)). In multivariate analysis, LC was higher in lesions with a Plpnning target volume (PTV) volume <  42 cm3 and BED10 ≥ 75 Gy. Patients with Karnofsky performance status <  90 showed higher out-field progression. SRT is an effective treatment for patients with oligometastases from CRC. Its low treatment-associated morbidity and acceptable LC make of SRT an option not only in selected cases. Further studies should be fo...
Source: Clinical and Experimental Metastasis - Category: Cancer & Oncology Source Type: research